Video

Long-Term Efficacy and Safety of Larotrectinib in Patients with Advanced TRK Fusion-Positive Thyroid Carcinoma

Dr. Waguespack reviews efficacy and safety data for larotrectinib in patients with TRK fusion-positive thyroid carcinoma.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    • Tropomyosin receptor kinase (TRK) fusions are rare but recurrent oncogenic drivers.
      • TRK expression is primarily limited to the nervous system
      • Three structurally related TRK receptors are encoded by three distinct genes
        • TRKA, TRKB and TRKC are encoded by NTRK1, NTRK2 and NTRK3, respectively
        • NTRK gene fusions encode TRK fusion proteins with highly active kinase activity that drive tumorigenesis
      • NTRK gene fusions have been identified across diverse pediatric and adult cancers
      • Occur in up to 1% of all solid tumors andin 5–25% of thyroid cancers
      • Larotrectinib is a first-in-class, highly selective, and CNS-active TRK inhibitor
    • Methods
      • 29 patients, both adult and pediatric, with measurable metastatic or locally advanced TRK fusion thyroid cancer
        • The primary endpoint for this study isobjective response rate and the secondary endpoints were duration of response, progression free survival, overall survival, and safety.
        • Adult patients received larotrectinib 100mg twice daily and pediatric patients received 100mg/m2 twice daily.
    • Results
      • Among 28 evaluable patients, ORR was 71% (95% confidence interval [CI] 51-87): 2 (7%) complete responses, 18 (64%) partial responses, 4 (14%) stable disease, 3 (11%) progressive disease, and 1 (4%) not determined.
      • ORR was 86% (95% CI 64-97) among patients with differentiated TC (DTC) and 29% (95% CI 4-71) among those with ATC.
        • Median time to response was 1.87 months (range: 1.64–3.68 months)
        • At the data cut-off, 6 patients (21%) had progressed with 4 (14%) continuing treatment post-progression
        • Patients with ATC were more likely to discontinue due to progressive disease than patients with DTC
        • Treatment was ongoing in 19 patients (66%) at data cut-off
        • Safety:
          • TEAEs were mainly Grade 1–2
          • Grade 3 TRAEs occurred in 2 (7%) patients: Anemia and lymphocyte count decreased
          • 2 (7%) patients had a Grade 5 TEAE - metastatic papillary thyroid cancer, tracheal hemorrhage in an anaplastic patient, both unrelated to larotrectinib
          • No patients discontinued treatment due to TEAEs; 2 patients with dose reductions
    • Conclusions
      • NTRK gene fusions are identified in various thyroid carcinoma histologies and across the age spectrum
      • Larotrectinib demonstrated a high ORR (71%) and rapid and durable disease control in patients with TRK fusion thyroid carcinoma, especially those with differentiated thyroid carcinoma
      • Larotrectinib demonstrated a favorable safety profile and was
        well-tolerated
      • Testing for NTRK gene fusions in advanced thyroid carcinoma patients requiring systemic therapy should be considered

    1. Waguespack SG, Drilon A, Lin JJ, et al. Long-Term Efficacy and Safety of Larotrectinib in Patients with Advanced TRK Fusion-Positive Thyroid Carcinomapresented at: 2021 American Thyroid Association, September 30-October 1, 2021; Abstract 15.

    Related Videos
    Tagraxofusp Achieves Anti-tumor Activity With Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
    Tagraxofusp Achieves Anti-Tumor Activity with Rapid Restoration of Normal Hematopoiesis in Treatment-Naïve Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Subanalysis of a Pivotal Trial
    First results of nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability high/ mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW
    First results of nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability high/ mismatch repair-deficient metastatic colorectal cancer from CheckMate 8HW
    CDAC CLL
    Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the phase 1 CaDAnCe-101 study
    Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
    Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma
    Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
    Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7)
    Phase 3 AMPLIFY Trial
    Fixed-Duration Acalabrutinib plus Venetoclax With or Without Obinutuzumab versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial
    RLY-2608
    Efficacy of RLY-2608, a mutant-selective PI3Kα inhibitor, in patients with PIK3CA-mutant HR+HER2- advanced breast cancer: ReDiscover trial
    BOVen
    Multicenter Phase II Trial of Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen) in Treatment-Naïve Chronic Lymphocytic Leukemia: 5-Year Follow Up, Retreatment Outcomes, and Impact of MRD Kinetics (ΔMRD400)
    RMC-6236
    Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)
    5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results
    5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results
    Related Content